ProCE Banner Activity

CE / CME

Key Strategies for Overcoming Barriers to HCV Elimination Among Men Who Have Sex With Men

This interactive video module provides in-depth expert perspectives on barriers impeding expanded treatment and cure of HCV infection among men who have sex with men along with an analysis of critical strategies for preventing HCV infection and promoting sexual health.

Pharmacists : 2.00 contact {hours} ({0.2} CEUs)

Physicians : maximum of 2.00 AMA PRA Category 1 {Credits}

Released: April 16, 2019

Expiration: April 15, 2020

No longer available for credit.

Share

Faculty

Daniel S. Fierer

Daniel S. Fierer, MD

Associate Professor
Department of Infectious Diseases
Icahn School of Medicine at Mount Sinai
Head, Co-infection Clinic
Jack Martin Fund
Mount Sinai Medical Center
New York, New York

W. David Hardy

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Mark S. Sulkowski

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Jointly provided by
ProCE Banner

Supporters

This activity is supported by independent educational grants from

AbbVie

Gilead Text

Partners

NHCN

ProCE Banner

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Devise strategies to overcome barriers to HCV treatment for MSM with HCV/HIV coinfection
  • Apply interventions that support HCV elimination efforts among MSM at high risk for onward transmission
  • Provide appropriate patient counsel on HCV reinfection risk and prevention strategies for MSM who are cured of current HCV infection

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Mark S. Sulkowski, MD

Associate Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Mark S. Sulkowski, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, and Merck & Co, Inc, and funds for research support (paid to Johns Hopkins University) from AbbVie, Assembly Bio, Gilead Sciences, and Proteus Digital Health.

Faculty Disclosure

Primary Author

Daniel S. Fierer, MD

Associate Professor
Department of Infectious Diseases
Icahn School of Medicine at Mount Sinai
Head, Co-infection Clinic
Jack Martin Fund
Mount Sinai Medical Center
New York, New York

Daniel S. Fierer, MD, has disclosed that he has received funds for research support and has ownership interest in Gilead Sciences.

W. David Hardy, MD

Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

W. David Hardy, MD, has disclosed that he has received consulting fees from Gilead Sciences, Merck & Co, Inc, and ViiV Healthcare and funds for research support (paid to his former institution) from Amgen, Gilead Sciences, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, American Society of Addiction Medicine, International Network for Hepatitis in Substance Users and HealthHCV.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.9 contact hours.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-749-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 16, 2019, through April 15, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.